Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.12.12.20247841: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources SARS-CoV-2 antibody detection: Sera from all patients were tested using the Abbott SARS-CoV-2 IgG assay and Architect i2000SR system, by staff in Oxford. Abbottsuggested: (Abbott, RRID:SCR_010477)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:We recognise …
SciScore for 10.1101/2020.12.12.20247841: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources SARS-CoV-2 antibody detection: Sera from all patients were tested using the Abbott SARS-CoV-2 IgG assay and Architect i2000SR system, by staff in Oxford. Abbottsuggested: (Abbott, RRID:SCR_010477)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:We recognise limitations of our study; including limited power, incomplete exposure history and the presence of confounders with control data comparisons. Whilst the impact of shielding and social distancing practices observed by patients must be considered when interpreting these seroprevalence rates, we consider these findings to be informative, providing evidence to support the continuation of biologics in the COVID-19 era, especially considering the emerging data of deleterious IBD outcomes in those who have discontinued IBD medications during the pandemic(8). We cannot comment on the durability of response with a single timepoint or whether seropositive patients are protected from re-infection, and therefore we highlight the need for larger, multicentre, prospective, longitudinal studies such as the ICARUS and CLARITY studies, in order to answer the questions of durability and strength of serological response, immunomodulation on SARS-CoV-2 course and risk stratification. These studies also have potential implications in the prioritisation of vaccine delivery in IBD cohorts.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-